title: Hepatitis G virus infection in chronic liver disease.
abstract: BACKGROUND
  The hepatitis G virus (HGV), a recently identified member of the Flaviviridae family, can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood.
  
  
  OBJECTIVE
  To evaluate the prevalence and meaning of HGV infection in a large series of patients with chronic liver disease.
  
  
  METHODS
  Two hundred volunteer blood donors, 179 patients with chronic hepatitis C, 111 with chronic hepatitis B, 104 with alcoholic liver disease, 136 with hepatocellular carcinoma, and 24 with cryptogenic chronic liver disease were studied.
  
  
  METHODS
  HGV RNA was investigated in serum samples by reverse transcription and polymerase chain reaction amplification of the 5' non-coding region of HCV and hybridisation to a specific probe. The main features of HGV RNA seropositive and seronegative patients were compared.
  
  
  RESULTS
  The prevalence of HGV infection was 3% in blood donors, 7% in chronic hepatitis C, 8% in chronic hepatitis B, 2% in alcoholic liver disease, 4% in hepatocellular carcinoma, and 8% in cryptogenic chronic liver disease. HGV infected patients tended to be younger than non-infected patients but no differences concerning sex, possible source of infection, clinical manifestations, biochemical and virological parameters, or severity of liver lesions were found.
  
  
  CONCLUSIONS
  The prevalence of HGV infection in chronic liver disease seems to be relatively low in our area. Infection with HGV does not seem to play a significant pathogenic role in patients with chronic liver disease related to chronic HBV or HCV infection or to increased alcohol consumption, or in those with cryptogenic chronic liver disease.
authors.affiliation: Department of Medicine, University of Barcelona Medical School, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Guilera
authors.forename: J C
authors.initials: JC
authors.lastname: Sáiz
authors.forename: F X
authors.initials: FX
authors.lastname: López-Labrador
authors.forename: E
authors.initials: E
authors.lastname: Olmedo
authors.forename: S
authors.initials: S
authors.lastname: Ampurdanés
authors.forename: X
authors.initials: X
authors.lastname: Forns
authors.forename: J
authors.initials: J
authors.lastname: Bruix
authors.forename: A
authors.initials: A
authors.lastname: Parés
authors.forename: J M
authors.initials: JM
authors.lastname: Sánchez-Tapias
authors.forename: M T
authors.initials: MT
authors.lastname: Jiménez de Anta
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001782:Blood Donors; D006528:Carcinoma, Hepatocellular / Q000821:virology; D002908:Chronic Disease; D005260:Female; D018067:Flaviviridae / Q000235:genetics; D006509:Hepatitis B / Q000821:virology; D006526:Hepatitis C / Q000821:virology; D006521:Hepatitis, Chronic / Q000821:virology; D006525:Hepatitis, Viral, Human / Q000150:complications; D006801:Humans; D008107:Liver Diseases / Q000821:virology*; D008108:Liver Diseases, Alcoholic / Q000821:virology; D008113:Liver Neoplasms / Q000821:virology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D015995:Prevalence; D012367:RNA, Viral / Q000032:analysis
chemical_list: D012367:RNA, Viral